z-logo
open-access-imgOpen Access
Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease
Author(s) -
Ankur Kumar,
Brooke Liang,
Murali Aarthy,
Sanjeev Kumar Singh,
Neha Garg,
Indira U. Mysorekar,
Rajanish Giri
Publication year - 2018
Publication title -
acs omega
Language(s) - Uncategorized
Resource type - Journals
ISSN - 2470-1343
DOI - 10.1021/acsomega.8b01002
Subject(s) - zika virus , ns3 , virology , protease , flavivirus , context (archaeology) , hydroxychloroquine , virus , biology , medicine , enzyme , infectious disease (medical specialty) , biochemistry , disease , covid-19 , hepatitis c virus , paleontology
Zika virus is a mosquito-transmitted flavivirus that causes devastating fetal outcomes in the context of maternal infection during pregnancy. An important target for drugs combatting Zika virus pathogenicity is NS2B-NS3 protease, which plays an essential role in hydrolysis and maturation of the flavivirus polyprotein. We identify hydroxychloroquine, a drug that already has approved uses in pregnancy, as a possible inhibitor of NS2B-NS3 protease by using a Food and Drug Administration-approved drug library, molecular docking, and molecular dynamics simulations. Further, to gain insight into its inhibitory potential toward NS2B-NS3 protease, we performed enzyme kinetic studies, which revealed that hydroxychloroquine inhibits protease activity with an inhibition constant ( K i ) of 92.34 ± 11.91 μM. Additionally, hydroxychloroquine significantly decreases Zika virus infection in placental cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom